No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Devices
Abbott Laboratories is a global healthcare company that discovers, develops, manufactures, and sells a wide range of health products through its subsidiaries worldwide. The company operates across four principal segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products division supplies generic pharmaceuticals addressing a diverse array of therapeutic areas, including gastrointestinal, cardiovascular, neurological, and hormonal conditions, alongside pain, fever, and inflammation management. This segment also provides anti-infective agents like clarithromycin, influenza vaccines, and products designed to regulate colon function. The Diagnostic Products division delivers a comprehensive suite of solutions for laboratory and point-of-care settings. These include advanced laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion, alongside molecular diagnostic systems for detecting and measuring infectious agents via DNA/RNA analysis. The segment also offers rapid lateral flow tests, specialized molecular point-of-care tests for conditions like HIV, SARS-CoV-2, influenza, RSV, and strep A, blood testing cartridges, cardiometabolic test systems, drug and alcohol screening, and both remote patient monitoring and consumer self-testing devices. Additionally, it provides informatics and automation solutions to streamline laboratory operations. The Nutritional Products segment is dedicated to offering pediatric and adult nutritional items. Lastly, the Medical Devices segment provides cardiovascular devices, including solutions for rhythm management, electrophysiology, heart failure, vascular interventions, and structural heart defects. The segment further encompasses diabetes care products and neuromodulation devices for the treatment of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories is headquartered in North Chicago, Illinois.
www.abbott.comNo one on the platform currently holds ABL.DE.
No tracked institution reports a position in ABL.DE as of their last filing.
No one on the platform has traded ABL.DE yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 10.9% | 15.6% | 11.5% | — | — | — |
| Rev. Growth % | 5.7% | 5.1% | ||||
| Profit Margin % | 14.7% | 18.6% | 13.4% | |||
| Free Cash Flow Margin % | 16.7% | 16.5% | 15.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $49.6B | +11.0% | $5.44 | $5.05–$5.53 | — | 1 |
| 2027 | $53.9B | +8.7% | $5.98 | $5.55–$6.08 | — | 1 |
| 2028 | $57.6B | +6.9% | $6.63 | $6.16–$6.74 | — | 1 |
| 2029 | $62.0B | +7.5% | $7.35 | $6.83–$7.47 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-16 | $1.12 | $1.15 | +2.7% |
| 2026-04-16 | $0.99 | $0.99 | +0.4% |
| 2026-01-22 | $1.27 | $1.28 | +0.8% |
| 2025-10-15 | $1.11 | $1.11 | +0.0% |
| 2025-07-17 | $1.07 | $1.07 | +0.0% |
| 2025-04-16 | $0.99 | $1.01 | +1.9% |
| 2025-01-22 | $1.30 | $1.29 | -0.8% |
| 2024-10-16 | $1.08 |
| $1.09 |
| +0.9% |